Advanced Oncotherapy Share Discussion Threads

[twirl] 21/6/2016 11:15

Reckon we have a buyer as online limits are 366/25k at 5.34/5.5p

Maybe that TW rascal

[typhoon] 21/6/2016 10:47

That is scary reading yet not surprising daijavu...TW's thoughts aside which as I have mentioned do not hold much water for me...I make my own decisions based on due diligence and research and some I win some I lose...but that is being a shareholder, for me this is a long term hold!

[daijavu] 21/6/2016 08:17

On the subject of TW. This is worth a read:

hxxps://sharetipstersuncovered.wordpress.com/2015/01/06/rivington-street-holdings-bedroom-fantasy-to-corporate-catastrophe/

[typhoon] 21/6/2016 07:44

Agree with you ALTOM and Proton therapy will be big if they can make this work on smaller machines than the traditional the market will be worldwide and huge as far as TW is concerned I am not always convinced of his advice or his motivations just my opinion of course

[altom] 21/6/2016 07:39

I regard myself as an Investor not a Trader. Catching the up and downs is too dangerous for me. A year from now the price will be around 10p and I will be pretty happy. Good news from Sinofi, Harley St. and/or updates on testing could see the share price double in a day.

[barnetpeter] 20/6/2016 22:03

I think TW is excellent at finding overpriced stuff. Not so good as finding cheap stuff. This stock still has a mkt cap of £70 million plus. Good to be out

[smarm] 20/6/2016 12:14

Could take longer, depends on what objections they receive.

S

[daijavu] 20/6/2016 11:35

The Planning application for Harley Street was sumitted to Westminster City Council on the 8th June 2016 and, all being well, ought to receive approval mid August.

[billweb] 20/6/2016 11:13

I would like to see the directors picking shares up at this level.

[standish11] 20/6/2016 10:38

Smarm
I agree. I am told by someone who is involved in the UCLH project that planning permission was granted before the demolition of the existing building commenced.

[smarm] 20/6/2016 09:51

They are currently installing a Proton machine in Huntley St London as part of UCLH. Obviously not the latest but planning permission obviously is obtainable.

TW's point is about the money and the company putting it up. Sorry but I think it's a perfectly valid red flag.

S

[igbertsponk] 20/6/2016 08:26

Always a bit late to the party is Tom.

[smarm] 20/6/2016 07:29

TW makes good point.

S

[tia1617] 20/6/2016 05:28

TW may be talking rubbish....but I don't see much substance arguing against it...either on here or from AVO.

[twirl] 19/6/2016 22:02

What a load of rubbish from Winnifreth.

However he along with Brexit has enabled me add at a really good price.

[werty5] 19/6/2016 20:59

Yep for some reason my phone is not having it but can log in fine on laptop.

[werty5] 19/6/2016 17:49

Ok might be just the fact i am using my phone. I will try and log on to sinophi via my laptop later.

[glibgibon] 19/6/2016 16:34

I can access the website.

[werty5] 19/6/2016 15:14

Just tried logging on to the Sinophi website and it would seem to have been taken down.

[oldvic] 19/6/2016 11:05

who shot the sherrif

[waterloo01] 19/6/2016 09:52

Doesn't make happy reading. Probably best to just trash talk re TW than actually do some rational analysis.

[igbertsponk] 17/6/2016 09:25

3p approaches. I did tell you!

[twirl] 16/6/2016 13:56

I raised concerns about a change of strategy from R&D to manufacture and treatment and here is the reply from AVO via Wallbrook.

I've spoken to the management team and have the following response to your letter.

Risk management is at the core of their business model. From a manufacturing perspective, this means that the company - together with Thales - has to be focused on the various options which will allow to mitigate risks and address the demand. With that in mind and as per the agreement, the Company and Thales are assessing various routes, including double-sourcing strategy and need to have different production lines (eg at Thales and other sites). So the two announcements are not contradictory. It is also worth noting that a key focus of Thales is to maximise efficiencies through the optimisation of its supply chain across the production site(s). To do this, Thales will "get paid" once the initial investment of AVO has been amortised (ie Thales will "not make margins" before the upfront investment needed for optimising the supply chain has been "recovered" by AVO).

Your second question was a bit unclear; so I summarised my understanding of the genesis of the Harley Street project. AVO's business model is focused on manufacturing (using suppliers), assembling, selling and maintaining LIGHT systems around the world. The Company has moved towards an outsourcing manufacturing model which is managed by Thales. Thales can therefore be seen as a "Tier-1" manufacturer acting as an active intermediary between AVO and its various suppliers such as Toshiba, VLD (a Philips spin-off), etc. However AVO is also expected to be "active" in the operations of the Harley Street Proton Therapy Centre through its partnership with Circle Health. In terms of responsibilities (and taking the RNS) Circle Health will take responsibility for all operational and clinical matters at the facility as well as the additional procurement, fit-out and facility testing requirements needed for full commissioning and beyond the testing required during the technical development of the system. Circle Health will also take responsibility for insurance provision for the centre. Advanced Oncotherapy will take responsibility for all technical matters. The rationale of this partnership is based on the fact that this centre will be the first one to treat patients in London and as such AVO wants to ensure this works as smoothly as possible. As in any JV, it would be logical to anticipate some exit clauses in the future to avoid any conflicting positions (ie manufacturer or operator).

In that regards, the Metric transaction provides a £24m financing to AVO. This allows AVO to complete the production of the first LIGHT system which will be installed into the London centre. Once the machine has been installed into the Harley Street Centre, then the Harley Street JV can repay that £24m facility. This is why the Metric transaction is a facility that has been put in place for the provision of vendor financing by AVO for the Harley Street project. That £24m funding is split into two tranches, the second tranche being dependent on the development of a manufacturing plant. The rationale for doing so is because the interests paid to Metric are largely in shares (at 10p) as opposed to cash. This is a way for the Company to manage cash more tightly, and incentivise Metric in the longer-term (please note the statement that "the Company and Metric Capital are exploring opportunities for further investment to facilitate the provision of vendor financing to AVO customers both in the UK and overseas."). This is also very interesting because it allows the Company to have a more effective tool to manage working capital requirements in the future, which is critical to avoid slowing down production ramp-up. As an implication of all of this, the returns of Metric are not only linked to the success of the Harley Street Proton Therapy Centre, but they are also linked to the ability of the Company to manufacture and sell more machines post Harley Street. This is why the Metric transaction has been structured in this specific way.

As you said in your email, I can't agree more with your statement that the management team and the Board are really impressive and in my opinion they have done very well in structuring deals in such a way that suppliers and customers become true partners with skin in the game. This is part of the strategy of the Company to focus on both the execution and financing visibility.

[daijavu] 16/6/2016 10:56

I'm out for the moment too. In fact I'm out of everything altogether until the dust has settled on Brexit. Brexit is looking more likely than ever.